Novartis Vaccines and Diagnostics, Via Fiorentina 1, Siena, Italy.
J Drug Target. 2010 Dec;18(10):752-70. doi: 10.3109/1061186X.2010.529143. Epub 2010 Nov 2.
Mucosal vaccine delivery potentially induces mucosal as well as systemic immune responses and may have advantages particularly for optimal protection against pathogens that infect the host through mucosal surfaces. However, the delivery of antigens through mucosal membranes remains a major challenge due to unfavorable physiological conditions (pH and enzymes) and significant biological barriers, which restrict the uptake of antigens. To improve mucosal vaccine delivery, the use of bioadhesive delivery systems offers numerous advantages, including protection from degradation, increasing concentration of antigen in the vicinity of mucosal tissue for better absorption, extending their residence time, and/or targeting them to sites of antigen uptake. Although some bioadhesives have direct immune stimulating properties, it appears most likely that successful mucosal vaccination will require the addition of vaccine adjuvants for optimal immune responses, particularly if they are to be used in an unprimed population. Thus, complex vaccine formulations and delivery strategies have to be carefully designed to appropriately stimulate immune response for the target pathogen. In addition, careful consideration is needed to define the "best" route for mucosal immunization for each individual pathogen.
黏膜疫苗传递有可能诱导黏膜和全身免疫反应,对于预防通过黏膜表面感染宿主的病原体可能具有优势。然而,由于不利的生理条件(pH 值和酶)和显著的生物学屏障,抗原通过黏膜的传递仍然是一个主要挑战,这些屏障限制了抗原的摄取。为了改善黏膜疫苗传递,使用生物黏附传递系统具有许多优点,包括防止降解、增加抗原在黏膜组织附近的浓度以更好地吸收、延长其停留时间和/或将其靶向抗原摄取部位。虽然一些生物黏附剂具有直接的免疫刺激特性,但似乎成功的黏膜疫苗接种将需要添加疫苗佐剂以获得最佳免疫反应,特别是如果它们要用于未接种人群。因此,必须仔细设计复杂的疫苗配方和传递策略,以适当刺激针对目标病原体的免疫反应。此外,还需要仔细考虑为每种病原体定义“最佳”的黏膜免疫途径。